Vad ska man tänka på vid dosering av Retsevmo® ▼ (selperkatinib)?

Detailed Information

• The recommended dose of selpercatinib in adult and adolescent patients 12 years of age or older is 

  • 160 mg orally twice daily for patients with an actual body weight ≥50 kg, and

  • 120 mg orally twice daily for patients with an actual body weight <50 kg.¹

• Patients should take the doses at approximately the same time every day.¹

• If a patient vomits or misses a dose, the patient should be instructed to take the next dose at its scheduled time. An additional dose should not be taken.¹

• Selpercatinib capsules must be swallowed whole if possible. lf a patient cannot swallow the capsules, then alternative administration instructions must be followed to ensure the integrity of the selpercatinib dose.²

• Selpercatinib may be taken with or without food unless coadministered with a PPI.¹

• Selpercatinib is taken orally twice daily until disease progression or unacceptable toxicity. Table 1 details the recommended dose of selpercatinib based on actual body weight.¹

Table 1. Recommended Selpercatinib Dosage^1,3

^a Based on actual patient weight.

References

1. Retsevmo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.